The selenium salt selenite (SeO3 2؊ ) is cytotoxic in low to moderate concentrations, with a remarkable specificity for cancer cells resistant to conventional chemotherapy. Our data show that selenium uptake and accumulation, rather than intracellular events, are crucial to the specific selenite cytotoxicity observed in resistant cancer cells. We show that selenium uptake depends on extracellular reduction, and that the extracellular environment is a key factor specific to selenite cytotoxicity. The extracellular reduction is mediated by cysteine, and the efficacy is determined by the uptake of cystine by the x c ؊ antiporter and secretion of cysteine by multidrug resistance proteins, both of which are frequently overexpressed by resistant cancer cells. This mechanism provides molecular evidence for the existence of an inverse relationship between resistance to conventional chemotherapy and sensitivity to selenite cytotoxicity, and highlights the great therapeutic potential in treating multidrug-resistant cancer.
S
elenite (SeO 3 2Ϫ ) efficiently inhibits the growth of malignant cells and studies suggest an inverse relationship between resistance to cytotoxic drugs and sensitivity to selenite (SeO 3 2Ϫ ) (1, 2). A major mechanism of selenite cytotoxicity is thought to be the generation of oxidative stress through intracellular redox cycling of the selenium metabolite selenide with oxygen and cellular thiols, producing nonstoichiometric amounts of superoxide and cellular disulfides. The induction of oxidative stress and consequent apoptosis has been demonstrated in numerous cancer cell lines (2) (3) (4) (5) (6) (7) (8) , but why this occurs only in malignant cells at easily achievable selenium plasma concentrations remains unclear.
With the assumption that the mechanistic explanation is intracellular, studies on differences in cellular uptake have been neglected. Already in the 1960s, selenite (SeO 3 2Ϫ ) was being used experimentally as a tumor-localizing agent. Neoplasms could be detected in brain and thorax in human subjects through i.v. administration of radioactive selenite ( 75 Se) (9) . Although at that time the cancer-specific cytotoxic effects of selenite were unknown, and low doses were used (approximately in the nM range in blood) (9) , early findings clearly demonstrated that cancer cells enrich selenium in vivo. These findings, combined with current knowledge of selenite's toxic effects on malignant cells, raise the possibility of a cancer-specific high-affinity selenium uptake mechanism that might explain cancer-specific selenite cytotoxicity at therapeutic selenite concentrations (M range).
In yeast, millimolar tolerance to selenite can be reduced to the micromolar range by the presence of excessive thiols in the growth medium through high-affinity uptake of a more reduced form of selenite, possibly selenide (10) . High-affinity uptake of selenium through the addition of extracellular thiols also has been demonstrated in a keratinocyte model (11) using nanomolar concentrations of selenite. Selenium uptake was prevented in keratinocytes by the anion channel blocker 4,4Ј-diisothiocyanostilbene-2,2Ј-disulphonic acid (DIDS) in the presence and absence of glutathione (GSH), suggesting that both selenite and selenide were taken up through these pathways but with different affinities.
The x c Ϫ cystine/glutamate antiporter facilitates the uptake of extracellular cystine in exchange for intracellular glutamate, and is widely expressed in different cancer cell lines as well as primary tumors (reviewed in ref. 12 ). The availability of cysteine is the limiting step in GSH synthesis (13) , and thus high cysteine availability is also important in the cellular defense against oxidative stress and may aid drug resistance. In extracellular plasma, cysteine levels are low (Ϸ10 M), and cystine levels are almost 10-fold higher (14) , giving x c Ϫ -expressing cancer cells access to a larger pool of cysteine. Overexpression of the x c Ϫ transport system in the HH514 Burkitt's lymphoma cell line was recently reported to have only limited impact on intracellular GSH levels but to drive a cystine/cysteine redox cycle resulting in high extracellular cysteine levels, thereby protecting the extracellular compartment from oxidative stress (15) .
The goal of the present study was to explore the connections among selenium uptake, selenite cytotoxicity, and the redox state of the microenvironment. We hypothesized that a reducing microenvironment dependent on the x c Ϫ antiporter could lead to a high-affinity selenium uptake that might explain cancer cellspecific selenite cytotoxicity.
Results
Selenite Cytotoxicity Is Determined by Selenium Uptake. We used 3 lung cancer cell lines with varying selenite sensitivity to explore the relationship between selenium uptake and selenite cytotoxicity [supporting information (SI) Table S1 ]. Uptake was measured in cells treated with a dose of 5 M for 5 h to explore whether selenium accumulation preceded cytotoxicity. The dose was chosen to be suitable for cells with varying sensitivity to selenite, including highly toxic (H157), borderline toxic (U2020), and nontoxic (H611). Selenium accumulation was greatest in the H157 cells (280 Ϯ 6 ng/mg total protein), less in the U2020 cells (60 Ϯ 9 ng/mg total protein), and undetectable in the H611 cells. These results correspond closely to the toxicity at the given doses and suggest that selenite toxicity is determined by the level of selenium accumulation in cells. Selenium Uptake Is Dependent on the Extracellular Redox State. To explore the connection between selenium uptake and the extracellular redox state, we measured the total production of extracellular thiols from the cells over time (Fig. 1A) . Extracellular thiol production was highest in the H157 cells, peaking at Ϸ110 M at 10 h, and was lower in the U2020 cells, peaking at Ϸ40 M at 20 h. Production in the H611 cells did not differ significantly from that seen in the control growth medium (Ϸ10 M). Extracellular thiol production showed a remarkable correlation with selenium uptake measured previously (R 2 ϭ 0.997) (Fig. 1B) , suggesting a strong relationship between a reductive microenvironment and high-affinity selenium uptake.
To verify this relationship and its connection to cytotoxicity, we artificially redox-modulated the extracellular compartment and treated the cells with 5 M selenite. Viability measured at 20 h was used as an endpoint. Extracellular reduction through inclusion of the cell-impermeable reductants GSH or Tris(2-carboxyethyl)phosphine (TCEP) led to increased selenite toxicity at equal concentrations (75 M) ( Fig. 2A) . Conversely, 500 M 55Ј-dithiobis-(2-nitrobenzoic acid) (DTNB) used as a cell-impermeable oxidant or thiol scavenger protected the cells from any toxic effects of selenite compared with the DTNB control. Additional experiments also showed that the presence of DTNB increased the IC-50 for selenite from Ϸ4 M to Ϸ40 M in the sensitive H157 cells.
To confirm that the increase in selenite sensitivity was due to a change in actual selenium uptake, we measured the selenium content in the highly sensitive H157 cells after treatment with DTNB and selenite and in the resistant H611 cells after treatment with TCEP and selenite (Fig. 2B) . The results clearly validate that the innate extracellular reductive capacity is crucial for selenite cytotoxicity and is mediated by an extracellular thiol-dependent high-affinity uptake mechanism.
The Major Part of Extracellular Thiols Is Cysteine. Protein precipitation of growth medium from the cells suggests that the dominant part of extracellular thiols is composed of lowmolecular weight compounds (data not shown). To characterize these compounds, we measured the reduced/total cysteine and GSH content over time using HPLC. The greatest increase in extracellular levels of reduced cysteine over time was seen in the H157 cells (peaking at Ϸ100 M in the growth medium at 10 h), followed by the U2020 cells (Ϸ30 M), and then the H611 cells (Ϸ5 M) (Fig. 3A) . The consumption rate of total medium cystine/cysteine also was highest in the H157 cells, followed by the U2020 cells and then the H611 cells. Extracellular levels of reduced GSH were enhanced in both the H157 (Ϸ6 M at 20 h) and U2020 cells (Ϸ3 M at 20 h), but remained low in all 3 cell lines compared with cysteine levels (Fig. 3B ).
Extracellular Thiol Production and, Consequently, Selenium Uptake and Cytotoxicity Are Dependent on Cystine Uptake Through the xc ؊ Cystine Antiporter. Because of the x c Ϫ antiporter's potential to mediate a reduced extracellular environment, along with its frequent and broad expression in different malignancies, we explored the antiporter's role in the differing extracellular redox states. We initially performed Western blot analysis to detect any major differences in expression. The x c Ϫ antiporter was expressed more markedly in both selenite-sensitive cell lines compared with the selenite-resistant H611 cell line (Fig. 3D) . To explore whether the antiporter activity is involved in mediating a reduced extracellular compartment, we used monosodium glutamate (MSG) to readily and specifically inhibit the x c Ϫ antiporter (16) . Adding MSG to the growth medium inhibited production of thiols in a dose-dependent manner (data not shown), and at 60 mM, MSG inhibited secretion of almost all thiols from the cell lines investigated (Fig. 3C) (compare with Fig. 1 A for untreated cells) . The data support an absolute dependence on cystine uptake through the x c Ϫ antiporter in the secretion of thiols, mainly cysteine, to the extracellular compartment.
To verify that inhibition of the x c Ϫ antiporter and, consequently, of cysteine secretion protects cells from selenite cytotoxicity, we treated cells with MSG and selenite. We found that MSG protected the cells from any toxic effects of selenite, an effect that could be reestablished by artificial reduction of the extracellular compartment (Fig. 4A) . This demonstrates that it is not the inhibition of the antiporter per se, but rather the resulting cessation of thiol secretion, that causes decreased cytotoxicity. The changes in cytotoxicity with MSG in the sensitive H157 cell line were found to result from the inhibition of selenium uptake (Fig. 4B) . Additional experiments also demonstrated that MSG shifted the IC-50 from Ϸ4 M to Ϸ20 M in the H157 cells, comparable to the IC-50 in the tolerant H611 cells.
The Multidrug Resistance Protein Efflux Pumps Are Involved in Cys-
teine Secretion. We used 2 competitive inhibitors, at nontoxic doses, to explore possible secretory pathways of reduced cysteine: MK571, an inhibitor of the multidrug resistance protein (MRP) family, and verapamil, an inhibitor of P-glycoprotein (Pgp). Verapamil had no significant effect on thiol secretion, but treatment with MK571 resulted in decreased extracellular thiol levels in a dose-dependent manner, as expected of a competitive inhibitor (Fig. 5A and B) .
Cytotoxicity of Both Seleno-Di-Glutathione and Selenocystine Are
Inhibited by DTNB and MSG. We also tested the redox active selenium compounds seleno-di-glutathione (GSSeSG) and selenocystine combined with DTNB and MSG in the H157 cells. GSSeSG was more toxic than selenite (data not shown), but its toxicity was significantly inhibited by DTNB and MSG, suggesting that reduction is required for uptake (Fig. S1B) . Selenocystine was less potent than selenite or GSSeSG (data not shown) but also was significantly inhibited by DTNB and MSG at toxic levels ( Fig. S1 A) , suggesting that it is taken up either in its reduced form as selenocysteine or as a selenocys-cysteine con- jugate (CysSe-Cys) through the x c Ϫ antiporter. These results indicate that our findings are general and apply to at least 3 common redox active forms of selenium.
The Uptake/Cytotoxicity Mechanism Is General and Not Limited to
Lung Cancer Cells. To explore whether our findings can be generalized, we tested cancer cell lines of different origins in a XTT [sodium 3Ј-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate] viability panel with selenite combined with TCEP, DTNB, MSG, or MSG ϩ TCEP. Hepatoma (HUH7) and neuroblastoma (SH5YSY) cell lines were used (Fig. S2) . The neuroblastoma cells, with an extracellular redox status similar to that of the resistant H611 cells, were highly resistant. In the hepatoma cells, which had an extracellular redox status similar to that of the U2020 cells, selenite was borderline toxic at given doses. TCEP markedly increased the toxicity of selenite in both cell lines, whereas DTNB inhibited all toxic effects. MSG also inhibited the toxic effects of selenite, but these effects were reestablished in combination with TCEP. These results are consistent with the findings in the lung cancer cells.
Discussion
Drug-resistant tumor cells have been shown to be particularly sensitive to selenite toxicity, with growth-inhibiting effects observed at low concentrations harmless to cell type-or patient-matched normal cells (2, 17) . The mechanisms behind this specificity remain unclear, however. To investigate the role of extracellular thiols in selenite toxicity, we treated cell lines of varying sensitivity with selenite and investigated the extracellular redox state, selenium uptake, and the expression and involvement of the x c Ϫ cystine/ glutamate antiporter. We found a clear association between extracellular thiols and selenite sensitivity and selenium uptake, which was verified by artificial redox modulation of the extracellular compartment. Furthermore, we found that the innate extracellular thiols were composed mainly of secreted cysteine through MRPs, driven by cystine uptake through the x c Ϫ antiporter. Our findings clearly demonstrate that x c Ϫ antiporter expression with concomitant secretion of cysteine, mainly through MRPs, is associated with selenite sensitivity, and that this is mediated through a high-affinity uptake by a reduced form of selenite.
Scintigraphic studies from the 1960s and 1970s demonstrated that selenium, administered i.v. as selenite, was enriched in cancer cells. In a study by Cavalieri et al. (9) , patients with tumors of the brain and chest were scanned, and all brain tumors were correctly localized with selenite. Selenium was enriched 10-to 13-fold compared with normal brain tissue, and positive scans were achieved as early as 4 h after injection, suggesting a high-affinity uptake. The x c Ϫ antiporter has been particularly associated with brain tumors, in which glutamate release also might be involved in destruction of neuronal tissue during tumor invasion (18) ; for example, the x c Ϫ antiporter was prominently expressed in all samples derived from 5 glioma patients (19) . Furthermore, sodium selenite has been shown to induce superoxide-mediated mitochondrial damage and subsequent autophagic cell death in 3 malignant glioma cell lines (20) . The in vivo enrichment of selenium in brain tumors, expression of the x c Ϫ antiporter in vivo and in cell lines, and the prominent pro-apoptotic effects of selenite in glioma cell lines are most likely linked to, and explained by, our findings.
X c Ϫ antiporter expression has been increasingly connected to tumor growth and drug resistance (15, 21, 22) and has been shown to be regulated by the antioxidant response element (ARE) (23) . Activation of the ARE induces several proteins known as phase II proteins, including MRPs plus enzymes regulating intracellular redox homeostasis. These proteins mediate cellular detoxification and protection from oxidative stress, but also are associated with drug resistance in cancer cells. The role of the x c Ϫ antiporter among the ARE-regulated proteins is to facilitate uptake of cystine, increasing intracellular cysteine availability and thereby enhancing GSH levels, which is important in drug resistance and the cellular defense against oxidative stress.
Although the x c Ϫ antiporter and related ARE-regulated proteins have been suggested as drug targets to reinduce chemotherapy sensitivity, our findings demonstrate that selenite cytotoxicity actually depends on the expression of these proteins. This suggests a possible relationship between selenite sensitivity and conventional drug resistance, which we indeed noted in our cell lines. We found that the H157 and U2020 cell lines, which prominently expressed the x c Ϫ antiporter, were the most sensitive to selenite, whereas the H611 cell line was highly seleniteresistant. Conversely, H611 was doxorubicin-sensitive, and H157 and U2020 were doxorubicin-resistant (data not shown). An inverse relationship has been demonstrated in lung cancer cells in a study exploring the effects on cellular redox protein thioredoxin reductase (TrxR) in the context of selenite treatment (1) . In that study, 3 parental drug-sensitive cell lines were used with doxorubicin-resistant sublines. In 2 cases, the doxorubicinresistant sublines were significantly more sensitive to selenite than their parental counterparts. Interestingly, in both of those cases, the drug resistance was conferred by MRP overexpression, whereas in the third subline, with similar selenite sensitivity as its parental cell line, drug resistance was conferred by Pgp. These findings are consistent with our results suggesting MRP, but not Pgp, as a secretory pathway of reduced cysteine. The roles of the ARE element and upstream regulators, such as Nrf2 (24) , in selenite cytotoxicity merit investigation.
Thiol secretion from cancer cells has been reported previously but is poorly characterized. Ceccarelli et al. (25) recently reported that secretion of nonprotein thiols from lung cancer cells affects tumor progression and response to pro-oxidants. They also demonstrated a dependence of thioredoxin 1 (Trx1) on levels of secreted nonprotein thiols. Trx1 is a NADPHdependent redox protein (via thioredoxin reductase) that reduces intracellular disulfides, including cystine, and thus may be involved as an intracellular limiting factor in the cystine/cysteine redox cycle. But almost complete inhibition of Trx1 protein expression with siRNA did not decrease the secretion of extracellular nonprotein thiols by 50% compared with control cells, indicating dependence on other redox molecules also capable of direct or indirect cystine reduction (possibly GSH, glutathione reductase, thioredoxin reductase, and glutaredoxins). Because of their mutual NADPH dependence (via glutathione reductase and thioredoxin reductase), levels of NADPH and NADPHregenerating enzymes, such as NADPH dehydrogenase, also must be considered. Thus the intracellular redox systems' impact on extracellular thiols and possible dual role in selenite cytotoxicity, also being protective against intracellular oxidative stress, merits further investigation. This complexity may explain the findings of Shen et al. (26) , who, in an effort to understand selenite cytotoxicity in connection with intracellular redox status, modulated GSH levels in hepatoma cells. Both increasing and decreasing intracellular glutathione levels sensitized the cells to selenite. Another interesting previously unexplained finding of Shen et al. (26) is that adding reduced GSH together with selenite extracelluarly produced the greatest increase in cytotoxicity, an effect likely explained by our model.
Control experiments revealed that the redox active selenium compounds seleno-L-cystine and GSSeSG also are dependent on extracellular thiols for cytotoxicity. The toxicity of GSSeSG was comparable to that of selenite, likely reflecting the efficient reduction to selenide and consequent uptake and intracellular redox cycling causing oxidative stress (3, 27) . But seleno-Lcystine was less toxic, as expected, because after uptake, it must undergo enzymatic metabolic degradation by ␤-lyase to selenide to achieve its full toxic potential. In addition, part of the internalized selenocysteine might be secreted back to the extracellular compartment along the same pathway as cysteine. Further experiments demonstrated that the related selenium compounds seleno-L-methionine and selenate were nontoxic up to millimolar concentrations and that MSG and DTNB had no significant effects (data not shown). This was as expected, because both compounds exert low or no redox reactivity. The data suggest that selenate and seleno-L-methionine are much less preferable from a therapeutic standpoint, at least in the context of the mechanism for cancer-specific toxicity of redox active forms of selenium presented here.
In conclusion, we have proposed a novel model in which selenite and possibly other redox active forms of selenium should be considered prodrugs activated by the reductive microenvironment of malignant cells. The reductive microenvironment is in turn dependent on cystine uptake through the x c Ϫ antiporter, intracellular reduction by NADPH-dependent redox protein systems, and secretion of cysteine to the extracellular environment by MRPs (Fig. 6) . The x c Ϫ antiporter, NADPH-dependent redox systems, and MRPs have been individually linked to tumor growth, progression, and multidrug resistance. Our findings highlight the unique therapeutic potential of reducible selenium compounds in treating cancer, especially in patients suffering 6 . Model for selenite cytotoxicity. The xc Ϫ cystine/glutamate antiporter facilitates the uptake of cystine, which is reduced intracellularly to cysteine by NADPH-dependent redox systems. A significant fraction of intracellular cysteine is resecreted into the extracellular compartment by MRPs, causing a reductive extracellular microenvironment. Extracellular reduction of selenite leads to a high-affinity uptake of a reduced form of selenite, possibly selenide, causing selenium accumulation and toxicity.
